title: Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
abstract: Bisphosphonates are effective for the treatment of osteoporosis despite recent reports of safety concerns such as atypical femur fracture. We conducted an ecological analysis of relevant media reports, oral bisphosphonate use, and fracture outcomes in the United States. Trends in media reports and public interest of bisphosphonates were quantified using data from Google Trends. Data from the Medical Expenditure Panel Survey (MEPS) and the National Inpatient Sample (NIS) were used to estimate the trends in oral bisphosphonate use among patients aged 55 years and older and hospitalizations for intertrochanteric and subtrochanteric fractures, respectively. These trends in the prevalence of oral bisphosphonate use and the age-adjusted incidence rate of intertrochanteric and subtrochanteric fractures were examined from 1996 to 2012. A series of spikes in Internet search activity for alendronate (Fosamax) occurred between 2006 and 2010 immediately following media reports of safety concerns. Oral bisphosphonate use declined by greater than 50% between 2008 and 2012 (p < 0.001) after increasing use for more than a decade. The decline was more common in patients with lower education levels. Intertrochanteric hip fractures declined from 1996 through 2006 (p < 0.001) and continued to decline from 2008 to 2012 (p < 0.05). Subtrochanteric and diaphyseal fractures showed a steady and significant increase from 2002 to 2011 (p < 0.05). However, the incidence decreased from a peak of 30.5 per 100,000 in 2011 to 26.7 per 100,000 in 2012. The plateauing and subsequent decline in oral bisphosphonate use since 2006 coincided with reports of safety concerns of bisphosphonates, despite the fact that U.S. Food and Drug Administration (FDA) and American Society of Bone and Mineral Research (ASBMR) reports did not recommend any safety restrictions on their use. This decline in oral bisphosphonate use was followed by the decline in the incidence of subtrochanteric and diaphyseal fractures.
authors.affiliation: National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Smita
authors.initials: S
authors.lastname: Jha
authors.affiliation: Clinical and Investigative Orthopedics Surgery (CIOS)/Intramural Research Program (IRP), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Clinical and Investigative Orthopedics Surgery (CIOS)/Intramural Research Program (IRP), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Laucis
authors.affiliation: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: Timothy
authors.initials: T
authors.lastname: Bhattacharyya
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D003625:Data Collection; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D017102:Fracture Healing / Q000187:drug effects*; D006620:Hip Fractures / Q000188:drug therapy* / Q000453:epidemiology*; D006801:Humans; D008297:Male; D008402:Mass Media; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy; D017063:Outcome Assessment, Health Care; D011639:Public Opinion; D014481:United States; D014486:United States Food and Drug Administration; D014807:Vitamin D / Q000008:administration & dosage
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D014807:Vitamin D; D019386:Alendronate
keywords: ANTIRESORPTIVES; BISPHOSPHONATE; EPIDEMIOLOGY; FRACTURE PREVENTION; GENERAL POPULATION STUDIES; OSTEOPOROSIS